Status:
RECRUITING
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
Lead Sponsor:
Eli Lilly and Company
Conditions:
Hypertension
Overweight or Obesity
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
GZL1 is an independent study conducted under the GZPL master protocol. GZL1 will evaluate the efficacy and safety of orforglipron for treatment of hypertension in participants with obesity or overweig...
Eligibility Criteria
Inclusion
- refer to the GZPL master protocol for screening eligibility.
Exclusion
- refer to the GZPL master protocol for screening eligibility.
Key Trial Info
Start Date :
April 30 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2027
Estimated Enrollment :
487 Patients enrolled
Trial Details
Trial ID
NCT06948435
Start Date
April 30 2025
End Date
September 1 2027
Last Update
December 24 2025
Active Locations (101)
Enter a location and click search to find clinical trials sorted by distance.
1
Elite Clinical Studies, LLC
Phoenix, Arizona, United States, 85018
2
Valley Clinical Trials, Inc.
Covina, California, United States, 91723
3
Valley Clinical Trials, Inc.
Northridge, California, United States, 91325
4
Chase Medical Research, LLC
Waterbury, Connecticut, United States, 06708